Eyenovia

115 articles about Eyenovia

• 

  FDA Action Alert: Sarepta, Protalix, Otsuka/Lundbeck and More

  5/8/2023

  The FDA's agenda includes an advisory committee meeting for Sarepta's delandistrogene moxeparvovec, which, if approved, would become the first gene therapy for Duchenne muscular dystrophy.

• Eyenovia to Report First Quarter 2023 Results on Thursday, May 11

  5/4/2023

  Eyenovia, Inc. today announced that the Company will release financial results for the first quarter ended March 31, 2023 on Thursday, May 11, 2023, after the markets close.

• Eyenovia Announces Poster Presentation at ARVO 2023

  4/24/2023

  Eyenovia, Inc. today announced a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting, which is being held April 23-27 in New Orleans.

• Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update

  3/30/2023

  Eyenovia, Inc. (Nasdaq: EYEN) today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2022.

• Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30

  3/23/2023

  Eyenovia, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 30, 2023, after the markets close.

• Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement

  2/28/2023

  Eyenovia, Inc. announced that Stephen Benjamin, an independent director on the Company’s Board of Directors, is stepping down to assume the role of Head of the White House’s Office of Public Engagement.

• Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

  2/15/2023

  Taiwan-based Formosa Pharmaceuticals announced that the company has entered into a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutics.

• Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals

  2/15/2023

  Eyenovia, Inc. announced that the company has entered into a development collaboration agreement with Taiwan-based Formosa Pharmaceuticals, Inc.

• Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas

  1/31/2023

  Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, showcased the Microdose Array Print Technology at CES 2023 in Las Vegas, Nevada, from Jan. 5-8.

• Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops

  1/12/2023

  Eyenovia, Inc. today announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatment administered via Optejet versus latanoprost+BAK administered via standard eye drops.

• Eyenovia Aims to Revolutionize Ophthalmology Devices With Microdose Array Print (MAP) Technology

  12/22/2022

  While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye dropper used has gone largely unchanged in the last century.

• Eyenovia Announces Participation at the 2023 International Consumer Electronics Show

  12/20/2022

  Eyenovia, Inc. (NASDAQ: EYEN) today announced that the company will participate at the 2023 International Consumer Electronics Show, which is being held January 5-8 at the Las Vegas Convention Center.

• Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

  12/13/2022

  Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for MydCombi™ ophthalmic spray.

• Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President

  12/8/2022

  Eyenovia, Inc. today announced that Bren Kern, who currently serves as Eyenovia’s Senior Vice President of Manufacturing and Operations, has been promoted to Chief Operating Officer and Corporate Vice President, effective January 1st.

• Eyenovia to Present at Upcoming BTIG Ophthalmology Day

  11/23/2022

  Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced management will present at the BTIG Ophthalmology Day taking place virtually on November 29, 2022.

• Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Eyenovia, Inc. announced its financial and operating results for the third quarter ended September 30, 2022.

• Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10, 2022

  11/3/2022

  Eyenovia, Inc. announced that the Company will release financial results for the third quarter ended September 30, 2022 on Thursday, November 10, 2022, after the markets close.

• Eyenovia to Present at the American Academy of Optometry’s Annual Meeting

  10/21/2022

  Eyenovia, Inc. announced the company will present at the 2022 American Academy of Optometry’s Annual Meeting, which is taking place from October 26-29, 2022, at the at the San Diego Convention Center.

• Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

  10/20/2022

  Eyenovia, Inc. (NASDAQ: EYEN) today announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia.

• Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.

  9/30/2022

  Eyenovia, Inc. today announced the planned retirement of lead independent director, Ken Lee, Jr., effective today, September 30, 2022.